Holen Sie sich die Stockscreener-App
4.70
12.44%
0.52
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation - Simply Wall St
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - BioSpace
DiaMedica Launches Phase 2 Trial for Novel Preeclampsia Treatment DM199 | DMAC Stock News - StockTitan
DiaMedica (DMAC) to Present at Craig-Hallum Conference: Spotlight on DM199 Stroke Treatment | DMAC Stock News - StockTitan
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - BioSpace
DiaMedica (DMAC) Sets Q3 2024 Earnings Call, Updates on DM199 Pipeline Progress | DMAC Stock News - StockTitan
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat
Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com
DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance
DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa
DiaMedica advances preeclampsia treatment with trial approval - Investing.com India
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment By Investing.com - Investing.com South Africa
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment - Investing.com India
DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
DiaMedica: Readying For REDUX Readout - RTTNews
Magnolia Capital Advisors LLC Buys New Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Point72 DIFC Ltd Acquires Shares of 2,848 Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Commonwealth Equity Services LLC Invests $303,000 in Diebold Nixdorf, Incorporated (NYSE:DBD) - Defense World
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Domino’s Pizza, Inc. (NYSE:DPZ) Position Lowered by Epoch Investment Partners Inc. - Defense World
Victory Capital Management Inc. Sells 10,924 Shares of Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Dolby Laboratories, Inc. (NYSE:DLB) Shares Sold by Federated Hermes Inc. - Defense World
Deftones’ Album Rises To A New Peak–Nearly 20 Years After Its Release - Forbes
Deutsche Telekom downgraded to Neutral from Outperform at Oddo BHF - TipRanks
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week - Simply Wall St
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7% - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 2.7% - MarketBeat
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com
DiaMedica Therapeutics Upcoming Conference Participation - Business Wire
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc. - Defense World
Vanguard Group Inc. Acquires 211,351 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - MarketBeat
Oppenheimer Reiterates “Outperform” Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics' (DMAC) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July - Defense World
Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 - Investing.com
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):